The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Previously untreated advanced unresectable/metastatic ESCC |
Tislelizumab + Investigator-chosen chemotherapy |
Placebo + Investigator-chosen chemotherapy |
Primary Endpoints: OS (ITT population) Key Secondary Endpoints: PFS, ORR, and DoR by investigator, OS in the PD-L1 score ≥10% subgroup, HRQoL, safety |
